TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1662232

Group type: EXPERIMENTAL
Intervention: Detection of DLIS using radioimmunoassay (RIA)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Detection of DLIS using affinity mediated immunoassay (ACA)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Detection of DLIS using fluorescence polarization immunoassay (TDX I)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Overall detection of DLIS using all 3 assays
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mean serum digoxin concentration
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Persistence of DLIS in patients with delayed allograft function
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Persistence of DLIS in patients without delayed allograft function
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Statistical significance of DLIS persistence
Number of subjects: 163
Study: 7158232

Group type: EXPERIMENTAL
Intervention: Oestradiol-17 beta orally (2-4 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oestradiol-17 beta cutaneously (3 mg)
Number of subjects: 38
Study: 6705172

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31664479

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30191421

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: CZP (combined doses)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 26915841

Group type: EXPERIMENTAL
Intervention: Early Steroid Withdrawal (ESW)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (steroid treatment)
Number of subjects: 71
Study: 23990451

Group type: EXPERIMENTAL
Intervention: Aprepitant (80 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 22052899

Group type: EXPERIMENTAL
Intervention: Real-time computerized decision support ON
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Real-time computerized decision support OFF
Number of subjects: 1407
Study: 21092442

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 18034343

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs
Number of subjects: 30
Study: 16155825

Group type: EXPERIMENTAL
Intervention: Compound branch chain amino acids injection (Aminic)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amino acids (MPR-F)
Number of subjects: 80
Study: 12772221

Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position after 30 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position after 60 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group in supine position
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups in supine position
Number of subjects: 22
Study: 10596256

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11
Study: 8686825

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with fentanyl
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 96
Study: 1923207

Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 55

Group type: COMPARATOR
Intervention: Novak
Number of subjects: 55
Study: 6122056

Group type: EXPERIMENTAL
Intervention: Pyrimethamine alone (7-day in-vivo test and 48 h in-vitro test)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (7-day in-vivo test)
Number of subjects: 24
Study: 30896757

Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 788
Study: 28449601

Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-practice
Number of subjects: 30
Study: 26188109

Group type: EXPERIMENTAL
Intervention: ONO-5334 (100mg slow-release tablets)
Number of subjects: 10
Study: 23386568

Group type: EXPERIMENTAL
Intervention: Fast Track prevention program
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Initial aggressive-disruptive behaviors and associated school readiness skills (cognitive ability, reading readiness, attention problems)
Number of subjects: 891
Study: 22108107

Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) and blue light-filtering IOL (Acrysof Natural SN60AT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acrylic UV light-filtering only IOL (Acrysof SA60AT)
Number of subjects: 30
Study: 19426750

Group type: EXPERIMENTAL
Intervention: 3rd derivative spatial filtering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard edge-detection schemes
Number of subjects: 0
Study: 16792148

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15460628

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg at 7.5 h, 100 mg at 3 h, and 100 mg at 0 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11248619

Group type: EXPERIMENTAL
Intervention: Holmium:yttrium‐aluminum‐garnet laser resection of the prostate (HoLRP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 120
Study: 9137222

Group type: EXPERIMENTAL
Intervention: 6-week moderate intensity supervised hospital-based exercise training program
Number of subjects: 49

Group type: COMPARATOR
Intervention: unsupervised low intensity home walking program (control group)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined outcomes for both groups
Number of subjects: 49
Study: 8187119

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg/day (n = 54)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (n = 53)
Number of subjects: 115
Study: 2976110

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) 150 μg over 30 minutes (protocol 1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) 200 μg over 30 minutes (protocol 2)
Number of subjects: 17
Study: 31822212

Group type: EXPERIMENTAL
Intervention: 8-month multicomponent intervention program
Number of subjects: 30
Study: 30808293

Group type: EXPERIMENTAL
Intervention: ceftobiprole
Number of subjects: 705
Study: 28279368

Group type: EXPERIMENTAL
Intervention: Care guided by advanced echocardiography (myocardial deformation and detailed diastolic function)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Imaging-guided care
Number of subjects: 618
Study: 26232545

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐cell cholera vaccine (Shanchol), 2 doses
Number of subjects: 123661

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐cell cholera vaccine (Shanchol), 1 dose
Number of subjects: 123661
Study: 23680937

Group type: EXPERIMENTAL
Intervention: Maximal isokinetic eccentric resistance training (IERT) knee extensor actions at 180° s(‐1) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 21458153

Group type: EXPERIMENTAL
Intervention: Udenafil 50mg once daily for 12 weeks
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Udenafil 75mg once daily for 12 weeks
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 18972724

Group type: EXPERIMENTAL
Intervention: Exercise therapy after electroacupuncture (EA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) after exercise therapy
Number of subjects: 0
Study: 16484135

Group type: EXPERIMENTAL
Intervention: Conventional Cigarettes (CC1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lower-tar Conventional Cigarettes (CC2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EHCSS1
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EHCSS2
Number of subjects: 110

Group type: COMPARATOR
Intervention: No Smoking
Number of subjects: 110
Study: 12955293

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 or 0.5 mg SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 10832598

Group type: EXPERIMENTAL
Intervention: NK cell counts
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: beta2‐microglobulin
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: sIL‐2r serum levels
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Immune cell counts and markers of activation
Number of subjects: 235
Study: 9199941

Group type: EXPERIMENTAL
Intervention: Dipyridamole‐echocardiography test (DET)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography test (EET)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 547
Study: 8222773

Group type: EXPERIMENTAL
Intervention: Tromantadine ointment 1%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (ointment base alone)
Number of subjects: 45
Study: 3302150

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 31860981

Group type: EXPERIMENTAL
Intervention: Norepinephrine at 4 μg/minute
Number of subjects: 97
Study: 29517802

Group type: EXPERIMENTAL
Intervention: WellWe intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 26761520

Group type: EXPERIMENTAL
Intervention: PrEP use disclosure
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Undetectable viral load (UVL) disclosure
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Calculated risk assessment for CAS
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Biomed-matching strategy
Number of subjects: 1395
Study: 24835623

Group type: EXPERIMENTAL
Intervention: Salvage arthroplasty
Number of subjects: 248

Group type: COMPARATOR
Intervention: Internal fixation (control)
Number of subjects: 248
Study: 22846250

Group type: EXPERIMENTAL
Intervention: Directive telephone counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondirective telephone counseling
Number of subjects: 0
Study: 19525241

Group type: EXPERIMENTAL
Intervention: Stretching (30 s static stretches of seven lower limb and trunk muscle groups before and after physical activity for 12 weeks)
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 2377
Study: 18700421

Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16459894

Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT)
Number of subjects: 0
Study: 12671031

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 4 weeks)
Number of subjects: 10
Study: 10227557

Group type: EXPERIMENTAL
Intervention: Continuous force application (100 g tipping force, elastics worn 24 hours per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Discontinuous force application (100 g tipping force, elastics worn 12 hours per day)
Number of subjects: 22
Study: 8912962

Group type: EXPERIMENTAL
Intervention: 5% C3F8
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 10% C3F8
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 16% C3F8
Number of subjects: 149
Study: 8256911

Group type: EXPERIMENTAL
Intervention: Unilateral cold dry air (UniCDA) nasal challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical atropine (0.225 mg) given ipsilateral to UniCDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical atropine given contralateral to UniCDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with lidocaine given ipsilateral to UniCDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with lidocaine
Number of subjects: 0
Study: 2951875

Group type: EXPERIMENTAL
Intervention: emiglitate
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31581959

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1400 mg/day of EPA and DHA)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 29644990

Group type: EXPERIMENTAL
Intervention: Distraction technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: EMLA (anaesthetic cream)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Distraction technique vs EMLA
Number of subjects: 72
Study: 27799236

Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 72
Study: 24951881

Group type: EXPERIMENTAL
Intervention: Web-based methotrexate self-injection education video (12 minutes) followed by in-person nurse education
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Web-based methotrexate self-injection education video
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard nurse-led teaching
Number of subjects: 29
Study: 23398978

Group type: EXPERIMENTAL
Intervention: Group follow-up after DAFNE education
Number of subjects: 437

Group type: COMPARATOR
Intervention: Individual clinic visits after DAFNE education
Number of subjects: 437
Study: 19430987

Group type: EXPERIMENTAL
Intervention: Kabat's rehabilitation (proprioceptive neuromuscular rehabilitation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-rehabilitated patients
Number of subjects: 20
Study: 18248533

Group type: EXPERIMENTAL
Intervention: Explosive-type heavy-resistance training (75-80% of 1 repetition maximum) for 12 weeks
Number of subjects: 2
Study: 16651507

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention program
Number of subjects: 441

Group type: COMPARATOR
Intervention: Continued care as usual
Number of subjects: 441
Study: 12504167

Group type: EXPERIMENTAL
Intervention: High dose of linoleic acid (15 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermediate dose of linoleic acid (7.5 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (15 g palmitic acid/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All experimental groups (high and intermediate linoleic acid and control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 30
Study: 10077397

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q-Gel) 60 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q-Gel)
Number of subjects: 47
Study: 7655127

Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg once daily
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg twice daily
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 2679960

Group type: EXPERIMENTAL
Intervention: Estradurin, 160 mg per month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 0
Study: 1255641

Group type: EXPERIMENTAL
Intervention: Intravenous 5% ethanol in 5% dextrose/water according to a weight‐time‐dose schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 31423685

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 210

Group type: COMPARATOR
Intervention: Degludec (50 U)
Number of subjects: 210
Study: 29050397

Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg, 50 mg, 150 mg, 300 mg, once daily for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (once daily for 8 weeks)
Number of subjects: 26
Study: 25033102

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in chronic total occlusions (CTO)
Number of subjects: 3589

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in non-chronic total occlusions (TO)
Number of subjects: 3589

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in non-occluded lesions
Number of subjects: 3589

Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in total occlusions (TO)
Number of subjects: 3589
Study: 24308224

Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (OLHDF)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 85
Study: 20602263

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenous
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ondansetron (control)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 89
Study: 19485818

Group type: EXPERIMENTAL
Intervention: CRx-102 (combination of dipyridamole and prednisolone)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16401678

Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy for diabetes (BFST-D)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Educational support group (ES)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 104
Study: 15223987

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 6705
Study: 11068213

Group type: EXPERIMENTAL
Intervention: Remote superficial femoral artery endarterectomy (RSFE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: In situ vein bypass
Number of subjects: 50
Study: 9261322

Group type: EXPERIMENTAL
Intervention: Topical 0.05% proparacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8173900

Group type: EXPERIMENTAL
Intervention: Surgical assessment of sepsis in the intersphincteric space
Number of subjects: 22

Group type: COMPARATOR
Intervention: Microbiological analysis (culture of gut organisms)
Number of subjects: 22
Study: 3296669

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mixed meal alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sorbitol and sucrose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All solid meals
Number of subjects: 9
Study: 28530142

Group type: EXPERIMENTAL
Intervention: TargetEd MAnageMent Intervention (TEAM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 38
Study: 28475123

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 0
Study: 25369906

Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard home visiting (SHV)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (IH-CBT and SHV)
Number of subjects: 93
Study: 24219054

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Baseline and 1 year assessment
Number of subjects: 788
Study: 21345781

Group type: EXPERIMENTAL
Intervention: Aspirin administration (150 to 325 mg) within 6 hours postoperatively
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-administration of aspirin
Number of subjects: 200
Study: 18492840

Group type: EXPERIMENTAL
Intervention: High protein diet (1.4 g.kg(‐1).d(‐1) protein and 3 daily servings of dairy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional high-carbohydrate diet (0.8 g.kg(‐1).d(‐1) protein and 2 daily servings of dairy)
Number of subjects: 130
Study: 17140522

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) without local analgesia (LA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional restorative method without local analgesia (LA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional restorative method with local analgesia (LA)
Number of subjects: 300
Study: 14574650

Group type: EXPERIMENTAL
Intervention: Treatment group received assessment, case management, and referral to appropriate resources.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group given a list of services.
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Treatment group (case management model).
Number of subjects: 188
Study: 11015798

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine administered to 60 children with 162 household contacts
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group received hepatitis A vaccine administered to 67 age-matched children with 166 household contacts
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Influenza vaccination for school-aged household contacts (aged 5-17 years)
Number of subjects: 149
Study: 9001837

Group type: EXPERIMENTAL
Intervention: Roxatidine 150 mg once nightly
Number of subjects: 192

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once nightly
Number of subjects: 192
Study: 1293305

Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg once daily (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Captopril 25‐50 mg twice daily (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Captopril 25‐50 mg twice daily
Number of subjects: 41
Study: 6336983

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of 500 mg of tetracycline in solution (pH = 2.8)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (solution of similar pH and appearance)
Number of subjects: 30
Study: 30392584

Group type: EXPERIMENTAL
Intervention: Apple Watch (Apple Inc, Cupertino, CA) for detecting irregular pulse
Number of subjects: 419093

Group type: EXPERIMENTAL
Intervention: Apple Watch notifications of pulse irregularity
Number of subjects: 419093
Study: 29502043

Group type: EXPERIMENTAL
Intervention: Research interviews
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Research questionnaires
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Audio recording of interviews
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall participation in the trial
Number of subjects: 40